

**Gates & Cooper LLP**

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045

**FAX RECEIVED**  
**DEC 07 2001**  
**GROUP 1600**

**FAX TRANSMISSION TO USPTO****OFFICIAL**

TO: Commissioner for Patents  
Attn: Examiner A. Davenport  
Patent Examining Corps  
Facsimile Center  
Washington, D.C. 20231

FROM: William J. Wood  
OUR REF.: G&C 130.32-US-01  
TELEPHONE: (310) 642-4144

Total pages, including cover letter: 5

**PTO FAX NUMBER: (703) 872-9306**

If you do NOT receive all of the pages, please telephone us at (310) 641-8797, or fax us at (310) 641-8798.

Title of Document Transmitted:	RESPONSE TO RESTRICTION REQUIREMENT
Applicant:	William P. Van Antwerp et al.
Serial No.:	09/344,676
Filed:	June 25, 1999
Group Art Unit:	1653
Our Ref. No.:	G&C 130.32-US-01

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP.

By: W. J. Wood  
Name: William J. Wood  
Reg. No.: 42,236

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

W. J. Wood  
Signature

12/6/01  
Date

WJW/sjm

G&amp;C 130.32-US-01


Due Date: December 6, 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	William P. Van Antwerp et al.	Examiner:	A. Davenport
Serial No.:	09/344,676	Group Art Unit:	1653
Filed:	June 25, 1999	Docket:	G&C 130.32-US-01
Title:	MULTIPLE AGENT DIABETES THERAPY		

**CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on December 6, 2001.

By:   
Name: William J. Wood

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

We are transmitting herewith the attached:


Transmittal sheet, in duplicate, containing a Certificate of Mailing or Transmission under 37 CFR 1.8.  
 Response to Restriction Requirement.

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers, if appropriate.

Please charge any additional fees or credit any overpayment to Deposit Account No. 50-0494 of Gates & Cooper LLP.  
A duplicate of this paper is enclosed.

**CUSTOMER NUMBER 22462.**

**GATES & COOPER LLP**  
Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, CA 90045  
(310) 641-8797

By:   
Name: William J. Wood  
Reg. No.: 42,236  
WJW/sjm

Due Date: December 6, 2001

13  
Harry  
Dec. 15, '01IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	William P. Van Antwerp et al.	Examiner:	A. Davenport
Serial No.:	09/344,676	Group Art Unit:	1653
Filed:	June 25, 1999	Docket:	G&C 130.32-US-01
Title:	MULTIPLE AGENT DIABETES THERAPY		

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being filed via facsimile transmission to the U.S. Patent and Trademark Office on December 6, 2001.

By: W. J. Wood  
Name: William J. Wood

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated November 6, 2001, please enter the following remarks.

REMARKSI. ELECTION OF SPECIES

The Office Action dated November 6, 2001 required a revised election of species of the invention from the species that the Examiner has designated: A (the each agent i, ii and iii); B (insulin sensitizer); and C (surfactants) (Office Action at page 2). In particular, the Examiner states that the election should include all of the species set forth in each of the groups to identify an ultimate species.

In response to this requirement, Applicants elect insulin (from the group of insulins designated by the Examiner as group "A(i)"), GLP-1 (from the group of insulin related peptides designated by the Examiner as group "A(ii)"), pioglitazone (from the group of insulin sensitizers designated by the Examiner as group "A(iii)" and "B"), and Genapol<sup>TM</sup>, a block ethylene/propylene